DK3033327T3 - (-)-(2r,3s)-2-amino-3-hydroxy-3-pyridin-4-yl-1-pyrrolidin-1-yl-propan-1-on-(l)-(+)-tartratsalt, fremgangsmåde til fremstilling og anvendelse heraf - Google Patents

(-)-(2r,3s)-2-amino-3-hydroxy-3-pyridin-4-yl-1-pyrrolidin-1-yl-propan-1-on-(l)-(+)-tartratsalt, fremgangsmåde til fremstilling og anvendelse heraf Download PDF

Info

Publication number
DK3033327T3
DK3033327T3 DK14755535.3T DK14755535T DK3033327T3 DK 3033327 T3 DK3033327 T3 DK 3033327T3 DK 14755535 T DK14755535 T DK 14755535T DK 3033327 T3 DK3033327 T3 DK 3033327T3
Authority
DK
Denmark
Prior art keywords
amino
hydroxy
pyrrolidin
propan
pyridin
Prior art date
Application number
DK14755535.3T
Other languages
English (en)
Inventor
Gyorgy F Ambrus
Katherine C Kurjan
Jacopo Zanon
Giovanna Libralon
Faveri Carla De
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Application granted granted Critical
Publication of DK3033327T3 publication Critical patent/DK3033327T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/56—Amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/02—Dicarboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235—Saturated compounds containing more than one carboxyl group
    • C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
    • C07C59/255—Tartaric acid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)

Claims (5)

10. Salt til anvendelse ifølge krav 8, hvor afasien er progressiv, ikke-flydende afasi.
11. Salt til anvendelse ifølge krav 8, hvor den neurodegenerative sygdom er udvalgt fra gruppen bestående af Alzheimers sygdom, kortikobasal degeneration, Creutzfeldt-Jacobs sygdom, frontotemporal lobar degeneration, Huntingtons sygdom, multipel sklerose, normaltrykshydrocephalus, organisk kronisk hjernesyndrom, Parkinsons sygdom, Picks sygdom, progressiv supranukleær parese og senildemens (Alzheimer-type).
12. Salt til anvendelse ifølge krav 8, hvor hjernelæsionen er udvalgt fra gruppen bestående af kronisk subduralt hæmatom, hjernerystelse, intracerebral blødning, encephalitis, meningitis, septis, lægemiddelforgiftning og lægemiddelmisbrug, eller hvor de psykiatriske forstyrrelser er udvalgt fra gruppen bestående af angstforstyrrelser, dissociative forstyrrelser, humørforstyrrelser, skizofreni og somatoforme og kunstigt skabte forstyrrelser.
13. Fremgangsmåde til fremstilling af (-)-(2R,3S)-2-amino-3-hydroxy-3-pyridin-4-yl-l-pyrrolidin-l-yl-propan-l-on-(L)-(+)-tartratsalt, hvilken fremgangsmåde omfatter: (a) omsætning af ethylisocyanacetat med pyrrolidin for at fremstille et mellemprodukt 1, der derefter omsættes med 4-pyridincarboxyaldehyd for at fremstille et mellemprodukt 2, hvor mellemprodukt 2 hydrolyseres til (+/-)-DL-f/7reo-2-amino-3-hydroxy-3-pyridin-4-yl-l-pyrrolidin-l-yl-propan-1-on-dihydrochlorid; (b) opløsning af (+/-)-DL-f77reo-2-amino-3-hydroxy-3-pyridin-4-yl-l-pyrrolidin-l-yl-propan-l-on-dihydrochloridet i tilstedeværelse af di-p-toluyl-L-vinsyre for at fremstille (-)-(2R,3S)-2-amino-3-hydroxy-3-pyridin-4-yl-l-pyrrolidin-l-yl-propan-l-on-di-p-toluoyl-L-tartrat; (c) omdannelse af (-)-(2R,3S)-2-amino-3-hydroxy-3-pyridin-4-yl-l-pyrrolidin-l-yl-propan-l-on-di-p-toluoyl-L-tartratet i tilstedeværelse af L- vinsyre til råt (-)-(2R,3S)-2-amino-3-hydroxy-3-pyridin-4-yl-l-pyrrolidin-l-yl-propan-l-on-(L)-(+)-tartratsalt og (d) krystallisering af det rå (-)-(2R,3S)-2-amino-3-hydroxy-3-pyridin-4-yl-l-pyrrolidin-l-yl-propan-l-on-(L)-(+) tartratsalt i tilstedeværelse af et egnet opløsningsmiddel for at fremstille oprenset (-)-(2R,3S)-2-amino-3-hydroxy-3-pyridin-4-yl-l-pyrrolidin-l-yl-propan-l-on-(L)-(+) tartratsalt.
14. Fremgangsmåde ifølge krav 13, hvor i trin (a) mellemprodukt 1 ikke er isoleret og er repræsenteret ved strukturen
eller hvor i trin (a) mellemprodukt 2 ikke er isoleret og er repræsenteret ved strukturen
eller hvor i trin (d) det egnede opløsningsmiddel omfatter methanol. 15. (-)-(2R,3S)-2-amino-3-hydroxy-3-pyridin-4-yl-l-pyrrolidin-l-yl-propan-l-on (!_)-(+) tartratsalt fremstillet ved hjælp af fremgangsmåden ifølge krav 13.
DK14755535.3T 2013-08-15 2014-08-14 (-)-(2r,3s)-2-amino-3-hydroxy-3-pyridin-4-yl-1-pyrrolidin-1-yl-propan-1-on-(l)-(+)-tartratsalt, fremgangsmåde til fremstilling og anvendelse heraf DK3033327T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361866155P 2013-08-15 2013-08-15
PCT/US2014/051007 WO2015023816A1 (en) 2013-08-15 2014-08-14 (-)-(2r,3s)-2-amino-3-hydroxy-3-pyridin-4-yl-1-pyrrolidin-1-yl-propan-1-one (l)-(+) tartrate salt, its method of production and use

Publications (1)

Publication Number Publication Date
DK3033327T3 true DK3033327T3 (da) 2018-04-16

Family

ID=51398940

Family Applications (1)

Application Number Title Priority Date Filing Date
DK14755535.3T DK3033327T3 (da) 2013-08-15 2014-08-14 (-)-(2r,3s)-2-amino-3-hydroxy-3-pyridin-4-yl-1-pyrrolidin-1-yl-propan-1-on-(l)-(+)-tartratsalt, fremgangsmåde til fremstilling og anvendelse heraf

Country Status (14)

Country Link
US (2) US9242935B2 (da)
EP (2) EP3336079A1 (da)
JP (1) JP6486358B2 (da)
CN (2) CN108794386B (da)
CA (1) CA2921385C (da)
DK (1) DK3033327T3 (da)
ES (1) ES2664749T3 (da)
HK (1) HK1224292A1 (da)
HU (1) HUE036381T2 (da)
NO (1) NO2960430T3 (da)
PL (1) PL3033327T3 (da)
PT (1) PT3033327T (da)
SI (1) SI3033327T1 (da)
WO (1) WO2015023816A1 (da)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2664749T3 (es) 2013-08-15 2018-04-23 Allergan, Inc. Sal (l)-(+)-tartrato de (-)-(2R,3S)-2-amino-3-hidroxi-3-piridin-4-il-1-pirrolidin-1-il-propan-1-ona, su método de producción y uso
US9992703B2 (en) * 2016-04-04 2018-06-05 Cisco Technology, Inc. Insertion of management packet into a deterministic track
WO2023154450A2 (en) * 2022-02-11 2023-08-17 Gilgamesh Pharmaceuticals, Inc. (ampa-pam)-nmda receptor antagonist combination therapy for treatment of mental conditions and disorders

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5545745A (en) * 1994-05-23 1996-08-13 Sepracor, Inc. Enantioselective preparation of optically pure albuterol
AU2002348261A1 (en) * 2001-11-26 2003-06-10 Genzyme Corporation Diastereoselective synthesis of udp-glucose : n-acylsphingosine glucosyltransferase inhibitors
PL1841743T3 (pl) 2005-01-26 2016-06-30 Allergan Inc Amidy kwasu 3-arylo-3-hydroksy-2-aminopropionowego, amidy kwasu 3-heteroarylo-3-hydroksy-2-aminopropionowego i powiązane związki o działaniu przeciwbólowym i/lub immunostymulacyjnym
WO2008011483A2 (en) * 2006-07-19 2008-01-24 Allergan, Inc. Methods for treating chronic pain using 1- (hetero) aryl-1-hydroxy 2,3-diamino-propyl amines and related compounds
WO2008011478A2 (en) * 2006-07-19 2008-01-24 Allergan, Inc. Methods for treating chronic pain using 3-aryl-3-hydroxy-2-amino-propionic acid amides, 3-heteroaryl-3-hydroxy-2-amino-propionic acid amides and related compounds
WO2008109286A1 (en) * 2007-03-06 2008-09-12 Allergan, Inc. Methods for treating cognitive disorders using 1-aryl-1-hydroxy-2,3-diamino-propyl amines, 1-heteroaryl-1-hydroxy-2,3-diamino-propyl amines and related compounds
DK2481407T3 (da) * 2007-03-06 2019-01-07 Allergan Inc Forbindelser til anvendelse ved behandling af kognitive lidelser
US8173683B2 (en) * 2007-03-06 2012-05-08 Allergan, Inc. Methods for treating cognitive disorders
ES2664749T3 (es) 2013-08-15 2018-04-23 Allergan, Inc. Sal (l)-(+)-tartrato de (-)-(2R,3S)-2-amino-3-hidroxi-3-piridin-4-il-1-pirrolidin-1-il-propan-1-ona, su método de producción y uso

Also Published As

Publication number Publication date
SI3033327T1 (en) 2018-05-31
CA2921385A1 (en) 2015-02-19
US20160347712A1 (en) 2016-12-01
PL3033327T3 (pl) 2018-07-31
EP3033327A1 (en) 2016-06-22
US20150051253A1 (en) 2015-02-19
HK1224292A1 (zh) 2017-08-18
CA2921385C (en) 2021-10-19
US9242935B2 (en) 2016-01-26
CN105555765A (zh) 2016-05-04
ES2664749T3 (es) 2018-04-23
PT3033327T (pt) 2018-04-04
CN108794386B (zh) 2021-06-22
JP2016528255A (ja) 2016-09-15
CN108794386A (zh) 2018-11-13
EP3336079A1 (en) 2018-06-20
HUE036381T2 (hu) 2018-07-30
CN105555765B (zh) 2018-05-25
US9540328B2 (en) 2017-01-10
NO2960430T3 (da) 2018-01-06
EP3033327B1 (en) 2018-01-03
JP6486358B2 (ja) 2019-03-20
WO2015023816A1 (en) 2015-02-19

Similar Documents

Publication Publication Date Title
JP5107058B2 (ja) 鎮痛活性および／または免疫賦活活性を有する３−ヘテロ環−３−ヒドロキシ−２−アミノプロピオン酸アミドおよび関連化合物
DK171694B1 (da) Krystallinsk paroxetinhydrochlorid, farmaceutisk præparat indeholdende dette samt fremstilling deraf
TWI299730B (en) Piperidine derivatives,processes for their preparation ,pharmaceutical composition containing them and their medical use
AU2014239995B2 (en) Salt of omecamtiv mecarbil and process for preparing salt
CA2542373A1 (fr) Derives de n-[phenyl(piperidin-2-yl)methyl] benzamide, leur preparation et leur application en therapeutique
CA2878006C (en) Carbamate/urea derivatives
JP7513349B2 (ja) ＧｌｙＴ１阻害剤の固体形態
DK3033327T3 (da) (-)-(2r,3s)-2-amino-3-hydroxy-3-pyridin-4-yl-1-pyrrolidin-1-yl-propan-1-on-(l)-(+)-tartratsalt, fremgangsmåde til fremstilling og anvendelse heraf
CN1826115B (zh) 取代的哌啶化合物及其用法
DE60319097T2 (de) N-aryl-piperidin-substituierte biphenylcarboxamide als hemmer der sekretion von apolipoprotein b
KR20230021075A (ko) 베타 아드레날린성 작용제의 형태 및 조성물
TW201202218A (en) Method for preparing acid addition salts of polyacidic basic compounds
CN115925699B (zh) 具有镇痛活性的稠环化合物及其制备方法与用途
TW200932224A (en) Soluble epoxide hydrolase inhibitors for treatment of metabolic syndrome and related disorders
JP2021500323A (ja) ムスカリンｍ１受容体陽性アロステリックモジュレーターであるヘテロアリール化合物
JP5888612B2 (ja) 縮合ピリジン化合物塩の結晶
TW202245746A (zh) Ｎ－（（ｒ）－２，３－二羥基丙氧基）—３，４—二氟—２—（２—氟—４—碘—苯基胺基)—苯甲醯胺之基本上純的形式ｉｖ之組合物及其用途
JP2004509106A (ja) ニコチン性アセチルコリン受容体アゴニストとしての（２−アザ−ビシクロ［２．２．１］ヘプト−７−イル）メタノール誘導体
JPH10503214A (ja) アミノメチル アリール化合物；ドーパミンレセプター亜型選択性リガンド
WO2007012761A1 (fr) Nouveaux composes 1,1-pyridinyl aminocyclopropanamines polysubstitues, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
JP2024507798A (ja) 抗コリンエステラーゼ活性を有する６－メチルウラシル誘導体およびその使用
WO2012030258A1 (ru) Гетероциклические низкомолекулярные sapp-миметики, фармацевтическая композиция, способы получения и применения
Thomas et al. Isatin derived morpholine and piperazine derivatives as acetylcholinesterase inhibitors
CN114315689A (zh) 二硫烷基邻苯二甲酰亚胺类化合物、其制备方法和用途
WO2017120532A1 (en) Polymorphs of a phosphate salt of quinuclidin-4-ylmethyl 4-methyl-1h-indole-3-carboxylate and uses thereof